drugset
Drugs / Pegylated-Proline-Interferon alpha-2b
last change Apr 2021 re-read 3 minutes ago

Pegylated-Proline-Interferon alpha-2b

Protein / enzyme biologic

Developed for
acquired polycythemia vera
Investigated by
AOP Orphan Pharmaceuticals AG · PharmaEssentia (Co-Sponsor for USA) · PharmaEssentia Corporation (for the U.S.)

Trials 2

today NCT02523638 · Ph 3 NCT02218047 · Ph 3
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02523638 Jul → Dec 2015 acquired polycythemia vera AOP Orphan Pharmaceuticals AG Completed No outcome recorded
Phase 3 NCT02218047 Nov 2014 → Apr 2021 acquired polycythemia vera AOP Orphan Pharmaceuticals AG Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Pegylated-Proline-Interferon alpha-2b ClinicalTrials.gov intervention name — accepted as the source's own label NCT02523638 ↗
1

NCT02218047 ↗
Modality Protein / enzyme biologic “pegylated proline interferon alpha-2b” NCT02218047 ↗